Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C40H56O3 |
Molecular Weight | 584.8708 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 3 / 3 |
E/Z Centers | 9 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(\C=C\C=C(C)\C=C\C(=O)[C@]1(C)C[C@@H](O)CC1(C)C)=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C2=C(C)C[C@@H](O)CC2(C)C
InChI
InChIKey=VYIRVAXUEZSDNC-RDJLEWNRSA-N
InChI=1S/C40H56O3/c1-29(17-13-19-31(3)21-23-36-33(5)25-34(41)26-38(36,6)7)15-11-12-16-30(2)18-14-20-32(4)22-24-37(43)40(10)28-35(42)27-39(40,8)9/h11-24,34-35,41-42H,25-28H2,1-10H3/b12-11+,17-13+,18-14+,23-21+,24-22+,29-15+,30-16+,31-19+,32-20+/t34-,35+,40+/m1/s1
Capsanthin, the red xanthophyll pigment, is used as a food additive approved by the European Union (EU) under the name as E160c. The common names for E160c are paprika extract, capsanthin or capsorubin. Capsanthin shows potent anti-adipogenic, lipolytic and fatty acid burning activities due to its potent adrenoceptor-beta2-agonistic activity. It was revealed, that capsanthin was not a thermogenic substance that is why it may be a good candidate for the development of new bioactive agent effective as a new anti-obese or insulin sensitivity enhancing substance.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: P07550|||Q53GA6|||Q9UCZ3 Gene ID: 154.0 Gene Symbol: ADRB2 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/28449555 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
PubMed
Title | Date | PubMed |
---|---|---|
Accumulation and clearance of capsanthin in blood plasma after the ingestion of paprika juice in men. | 1997 Aug |
|
Carotenoids in human blood plasma after ingesting paprika juice. | 2000 May |
|
[Spectral characterization for capsanthin molecule with in vitro oxidative defense reaction]. | 2014 Feb |
|
Carotenoids exclusively synthesized in red pepper (capsanthin and capsorubin) protect human dermal fibroblasts against UVB induced DNA damage. | 2016 Aug 31 |
|
In vivo and in vitro evaluation for nutraceutical purposes of capsaicin, capsanthin, lutein and four pepper varieties. | 2016 Dec |
|
Capsanthin Inhibits both Adipogenesis in 3T3-L1 Preadipocytes and Weight Gain in High-Fat Diet-Induced Obese Mice. | 2017 May 1 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/9237940
Supplementing capsanthin-rich paprika juice for 1 wk (equivalent to three doses of 5.4 micromol capsanthin/d; 16.2 micromol/d), the level of capsanthin reached a plateau (0.10-0.12 micromol/L) between d 2 and 7 and was not detectable by d 16.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/28449555
Capsanthin Inhibits adipogenesis in 3T3-L1 preadipocytes. During adipogenesis in 3T3-L1 preadipocytes, capsanthin (10 uM) inhibited adipogenesis (IC₅₀; 2.5 μM) and also showed lipolytic activity in differentiated adipocytes from the preadipocytes (ED₅₀; 872 nM). It was found, that the pharmacological activity of capsanthin on adipogenesis in 3T3-L1 was mainly due to its adrenoceptor-β₂-agonistic activity
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
5281228
Created by
admin on Fri Dec 15 20:39:40 GMT 2023 , Edited by admin on Fri Dec 15 20:39:40 GMT 2023
|
PRIMARY | |||
|
465-42-9
Created by
admin on Fri Dec 15 20:39:40 GMT 2023 , Edited by admin on Fri Dec 15 20:39:40 GMT 2023
|
PRIMARY | |||
|
Capsanthin
Created by
admin on Fri Dec 15 20:39:40 GMT 2023 , Edited by admin on Fri Dec 15 20:39:40 GMT 2023
|
PRIMARY | |||
|
DTXSID10905012
Created by
admin on Fri Dec 15 20:39:40 GMT 2023 , Edited by admin on Fri Dec 15 20:39:40 GMT 2023
|
PRIMARY | |||
|
420NY1J57N
Created by
admin on Fri Dec 15 20:39:40 GMT 2023 , Edited by admin on Fri Dec 15 20:39:40 GMT 2023
|
PRIMARY | |||
|
7977
Created by
admin on Fri Dec 15 20:39:40 GMT 2023 , Edited by admin on Fri Dec 15 20:39:40 GMT 2023
|
PRIMARY | |||
|
3375
Created by
admin on Fri Dec 15 20:39:40 GMT 2023 , Edited by admin on Fri Dec 15 20:39:40 GMT 2023
|
PRIMARY | |||
|
C006889
Created by
admin on Fri Dec 15 20:39:40 GMT 2023 , Edited by admin on Fri Dec 15 20:39:40 GMT 2023
|
PRIMARY | |||
|
207-364-1
Created by
admin on Fri Dec 15 20:39:40 GMT 2023 , Edited by admin on Fri Dec 15 20:39:40 GMT 2023
|
PRIMARY | |||
|
m3041
Created by
admin on Fri Dec 15 20:39:40 GMT 2023 , Edited by admin on Fri Dec 15 20:39:40 GMT 2023
|
PRIMARY | Merck Index |
SUBSTANCE RECORD